TransMedics Group, Inc. (NASDAQ:TMDX) Given Average Recommendation of “Moderate Buy” by Analysts

TransMedics Group, Inc. (NASDAQ:TMDX) has been given a consensus recommendation of “Moderate Buy” by the ten research firms that are currently covering the firm, Marketbeat reports. Four analysts have rated the stock with a hold rating and six have given a buy rating to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $144.25.

TMDX has been the topic of a number of analyst reports. Canaccord Genuity Group boosted their price objective on TransMedics Group from $147.00 to $148.00 and gave the company a “buy” rating in a research note on Wednesday, December 17th. Zacks Research downgraded TransMedics Group from a “strong-buy” rating to a “hold” rating in a research note on Monday, October 6th. Jefferies Financial Group assumed coverage on TransMedics Group in a research report on Monday, October 13th. They set a “buy” rating and a $145.00 price target on the stock. Morgan Stanley increased their price target on shares of TransMedics Group from $123.00 to $135.00 and gave the stock an “equal weight” rating in a report on Tuesday, December 2nd. Finally, Needham & Company LLC raised their price objective on shares of TransMedics Group from $148.00 to $166.00 and gave the company a “buy” rating in a research report on Monday, December 8th.

TransMedics Group Stock Performance

Shares of TMDX stock opened at $138.49 on Wednesday. The firm’s 50 day moving average is $133.78 and its 200 day moving average is $123.25. The stock has a market capitalization of $4.73 billion, a P/E ratio of 56.07 and a beta of 2.03. TransMedics Group has a 12 month low of $60.46 and a 12 month high of $156.00. The company has a current ratio of 7.69, a quick ratio of 7.13 and a debt-to-equity ratio of 1.43.

TransMedics Group (NASDAQ:TMDX) last issued its earnings results on Wednesday, October 29th. The company reported $0.66 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.37 by $0.29. The business had revenue of $143.82 million for the quarter, compared to analysts’ expectations of $145.33 million. TransMedics Group had a net margin of 16.20% and a return on equity of 31.42%. The business’s revenue for the quarter was up 32.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.12 EPS. On average, sell-side analysts anticipate that TransMedics Group will post 1 earnings per share for the current year.

Insiders Place Their Bets

In other TransMedics Group news, CFO Gerardo Hernandez sold 920 shares of the firm’s stock in a transaction on Thursday, December 4th. The shares were sold at an average price of $139.62, for a total value of $128,450.40. Following the completion of the transaction, the chief financial officer directly owned 15,064 shares of the company’s stock, valued at $2,103,235.68. This trade represents a 5.76% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director David Weill sold 5,000 shares of the business’s stock in a transaction on Wednesday, December 3rd. The shares were sold at an average price of $138.64, for a total transaction of $693,200.00. Following the transaction, the director owned 12,134 shares of the company’s stock, valued at $1,682,257.76. This trade represents a 29.18% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 8,920 shares of company stock worth $1,257,310 in the last three months. 7.00% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On TransMedics Group

A number of institutional investors have recently added to or reduced their stakes in TMDX. Amalgamated Bank increased its position in shares of TransMedics Group by 0.8% during the second quarter. Amalgamated Bank now owns 9,586 shares of the company’s stock valued at $1,285,000 after acquiring an additional 80 shares in the last quarter. Canada Pension Plan Investment Board boosted its stake in TransMedics Group by 2.9% during the 2nd quarter. Canada Pension Plan Investment Board now owns 3,600 shares of the company’s stock valued at $482,000 after purchasing an additional 100 shares during the last quarter. US Bancorp DE boosted its stake in TransMedics Group by 24.2% during the 3rd quarter. US Bancorp DE now owns 533 shares of the company’s stock valued at $60,000 after purchasing an additional 104 shares during the last quarter. Smartleaf Asset Management LLC increased its holdings in shares of TransMedics Group by 24.5% in the 2nd quarter. Smartleaf Asset Management LLC now owns 548 shares of the company’s stock worth $72,000 after purchasing an additional 108 shares in the last quarter. Finally, Allworth Financial LP increased its holdings in shares of TransMedics Group by 74.3% in the 3rd quarter. Allworth Financial LP now owns 265 shares of the company’s stock worth $30,000 after purchasing an additional 113 shares in the last quarter. 99.67% of the stock is currently owned by institutional investors.

About TransMedics Group

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.